Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Study of KW-2449 in Acute Myelogenous Leukemia.

Trial Profile

Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Study of KW-2449 in Acute Myelogenous Leukemia.

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 09 Apr 2012

At a glance

  • Drugs KW 2449 (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions
  • Most Recent Events

    • 28 Apr 2010 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.
    • 28 Apr 2010 Actual patient number (14) added as reported by ClinicalTrials.gov.
    • 02 Apr 2010 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top